This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Pomerantz LLP Files Class Action...
Regulatory class action lawsuit

Pomerantz LLP Files Class Action Against REGENXBIO

Analysis based on 51 articles · First reported Jan 30, 2026 · Last updated Mar 08, 2026

Sentiment
-20
Attention
2
Articles
51
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of the class action lawsuit against REGENXBIO, driven by the United States===Food and Drug Administration's clinical hold on its gene therapies. This event highlights regulatory risks in the biotechnology sector and can lead to increased scrutiny of similar companies.

Biotechnology Legal Services
Event Summary

Pomerantz LLP has filed a class action lawsuit against REGENXBIO Inc. following a significant drop in the company's stock price. The decline was triggered by the United States===Food and Drug Administration's decision to place a clinical hold on REGENXBIO's investigational gene therapies, RGX-111 for MPS I and RGX-121 for MPS II. The hold was initiated after a preliminary analysis revealed a case of neoplasm in a participant treated with RGX-111. Investors who purchased REGENXBIO securities during the Class Period have until April 14, 2026, to seek appointment as Lead Plaintiff in the lawsuit, which alleges securities fraud and other unlawful business practices by REGENXBIO and its officers/directors.

Key Actions
100 United States===Food and Drug Administration placed clinical hold on investigational gene therapies REGENXBIO
95 United States===Food and Drug Administration placed clinical hold on gene therapies REGENXBIO
90 Pomerantz LLP filed class action lawsuit REGENXBIO
85 REGENXBIO stock price fell
70 Pomerantz LLP investigating claims on behalf of investors REGENXBIO
Entities Involved
stock
REGENXBIO
REGENXBIO is facing a class action lawsuit after the United States===Food and Drug Administration placed a clinical hold on its investigational gene therapies, RGX-111 and RGX-121. This news caused REGENXBIO's stock price to fall significantly, indicating negative market sentiment and potential financial repercussions from the lawsuit.
Importance 100 Sentiment -70
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration placed a clinical hold on REGENXBIO's gene therapies, RGX-111 and RGX-121, due to a reported neoplasm in a study participant. This regulatory action directly led to the decline in REGENXBIO's stock price and the subsequent class action lawsuit.
Importance 80 Sentiment 0
priv
Pomerantz LLP
Pomerantz LLP has filed a class action lawsuit against REGENXBIO, representing investors who suffered losses due to the clinical hold on REGENXBIO's gene therapies. This action positions Pomerantz LLP as a key player in seeking damages for affected shareholders.
Importance 70 Sentiment 20
exch
Nasdaq
REGENXBIO is listed on Nasdaq, and its stock price fell significantly following the news of the clinical hold and the class action lawsuit.
Importance 10 Sentiment 0
Relationships
Pomerantz LLP related ↔ REGENXBIO
Pomerantz LLP related ↔ United States===Food and Drug Administration
REGENXBIO related ↔ United States===Food and Drug Administration
United States===Food and Drug Administration related ↔ REGENXBIO
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.